Omada Health Dividends and Buybacks
Dividend criteria checks 0/6
Omada Health does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-1.1%
Buyback Yield
| Total Shareholder Yield | -1.1% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
OMDA: Leadership Transition And Index Shift Will Shape Balanced Future Returns
Analysts now place Omada Health's fair value at $22.00, up from $16.56, reflecting revised assumptions for revenue, profit margins, and a higher future P/E multiple. What’s in the News for Omada Health Omada Health plans a CEO transition on January 1, 2027.Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
Summary Omada Health (OMDA) delivered strong Q2 results, with 43% revenue growth, margin expansion, and positive adj. EBITDA, reinforcing my buy rating. OMDA’s product expansion, especially in diabetes and hypertension, is driving higher revenue per member and improving customer-lifetime-value through multi-program adoption. Channel partnerships with PBMs and health plans are lowering CAC, supporting scalable growth and better unit economics, while AI initiatives further enhance operational leverage. Valuation remains attractive; even conservative multiples suggest significant upside if OMDA sustains >40% revenue growth, though partner concentration and investment needs are key risks. Read the full article on Seeking AlphaOMDA: CEO Transition And Lower Growth Assumptions Will Pressure Future Returns
Analysts now place Omada Health's fair value at $16.56 per share, compared with the prior $15.00. The revised estimate reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E levels.
OMDA: Index Reclassification And Eli Lilly Partnership Will Drive Future Upside
Analysts now place Omada Health's fair value at $24.58 per share, compared with the prior $28.90. They cite updated views on revenue growth, profit margins, the discount rate, and future P/E assumptions.
OMDA: GLP-1 Care Partnership Will Drive Future Earnings Re-Rating
Analysts have trimmed their fair value estimate for Omada Health from $33.00 to $30.00, pointing to updated assumptions around revenue growth, discount rate, profit margin, and future P/E as the main drivers of the shift. What’s in the News for Omada Health Omada Health is set to introduce Omada Identity Sovereign, a containerized identity governance solution aimed at organizations with strict digital sovereignty requirements in Europe, with availability targeted for early 2027.OMDA: GLP-1 Program Reliance Will Drive Lower Future Return Expectations
Analysts have adjusted their Omada Health fair value estimate down from $17.53 to $15.00, as they now apply a slightly higher discount rate and expect lower revenue growth. This is partly offset by assumptions for a higher profit margin and a lower future P/E multiple.Is Omada Health, Inc. (NASDAQ:OMDA) Trading At A 34% Discount?
Key Insights Omada Health's estimated fair value is US$23.60 based on 2 Stage Free Cash Flow to Equity Omada Health's...With A 26% Price Drop For Omada Health, Inc. (NASDAQ:OMDA) You'll Still Get What You Pay For
Omada Health, Inc. ( NASDAQ:OMDA ) shareholders that were waiting for something to happen have been dealt a blow with a...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if OMDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OMDA's dividend payments have been increasing.
Dividend Yield vs Market
| Omada Health Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (OMDA) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.0% |
| Industry Average (Healthcare) | 2.0% |
| Analyst forecast (OMDA) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate OMDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OMDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate OMDA's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OMDA has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/24 11:35 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omada Health, Inc. is covered by 14 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Saket Kalia | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |